Monday, May 20, 2019
IBB 103.77 0.67 (0.64%)XBI 82.56 0.93 (1.11%)
Ticker Current Price Change Graph
IBB 103.77 0.67 (0.64%)
XBI 82.56 0.93 (1.11%)
Last updated: ago
Sign in to Endpoints
Menu Search Chat
  • Special Reports
  • Events
  • ENDPOINTS 100
  • News
  • Protocols
  • Bioregnum
  • Endpoints Careers
  • About
  • Advertise
  • Privacy Policy
  • Reader center

Dana-Farber’s 4-year legal battle shines a light on the origins of PD-1 research — forcing a reckoning on who pioneered the landmark cancer breakthrough

by John Carrollenvelope — on May 19, 2019 01:03 PM EDT
Updated: 10:39 PM

Under fire for Truvada US pricing at House hearing, Gilead chief O’Day touts R&D costs, asserts governments patents are void

by Natalie Groverenvelope — on May 17, 2019 10:28 AM EDT

EMA imposes formal limit on Xeljanz prescription as regulators continue to review safety concerns

by Amber Tongenvelope — on May 17, 2019 10:20 AM EDT

Biogen exec Paul McKenzie heads to CSL as COO; Pulmatrix CEO resigns

by Kathy Wongenvelope — on May 17, 2019 10:16 AM EDT
Updated: 10:49 AM

AbbVie concedes another PhIII cancer drug flop as glioblastoma defeats latest assault

by John Carrollenvelope — on May 17, 2019 09:34 AM EDT
Updated: 09:37 AM

Following its latest setback, Achillion posts some encouraging PoC data for lead drug

by John Carrollenvelope — on May 17, 2019 08:49 AM EDT

Takeda, Frazier create Phathom Pharmaceuticals to spur development of GI drug Vonoprazan in $140M play

by Natalie Groverenvelope — on May 17, 2019 08:29 AM EDT
Updated: 10:15 AM

UPDATED: Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead

by John Carrollenvelope — on May 17, 2019 07:27 AM EDT
Updated: 09:05 AM

All in on novel target GSK-3β, Actuate Therapeutics raises $21M+ to bankroll ambitious PhI/II

by Amber Tongenvelope — on May 17, 2019 06:55 AM EDT

Four years after EU approval, NICE finally backs Revlimid use in certain first-line multiple myeloma patients

by Natalie Groverenvelope — on May 17, 2019 06:39 AM EDT
Updated: 07:21 AM

  • 1
  • 2
  • 3
  • 510

Contact Endpoints News

You can also contact John Carroll, Editor at john@endpointsnews.com

← Go back
  • Endpoints Careers
  • About Endpoints
  • Privacy Policy
  • Advertise

copyright 2019 Endpoints Company

Yes, I'd like to subscribe No, thanks
I'm already a subscriber
Thank you for staying with us. It's great to have you on board!
Aww, shucks. Perhaps you can tell us what we could do to make you interested in subscribing?
Sure No
← Go back

Sign in to Endpoints News

I forgot my password Request a magic link
← Go back

Request a magic link

Enter your email below to get a Magic link which lets you sign in quickly without using a password.
Please note the Magic link is one-time use only and valid for only 24 hours.
← Go back

Set a new password

We will send you a link, with which you will be able to set a new password.
Please note this link is one-time use only and valid for only 24 hours.